Crucial targets of Hsp90-active drugs vary in different cell types, and Hsp90 is permissive for the development of mutant EGFR-dependent lung cancers, these kinase domain mutants are degraded by Hsp90 inhibitors [20, 33]. Here, HSP90AA1 is linked to lung carcinoma.